Kinnate Biopharma Inc. (NasdaqGS:KNTE) acquired the remaining stake in Kinnjiu Biopharma Limited for $24 million on February 17, 2023. The consideration includes $9.1 million in cash and $14.9 million in Company stock, which resulted in the issuance of 2,200,000 shares of Company stock tWilson Sonsini Goodrich & Rosati, P.C. served as legal advisor to Kinnate Biopharma Inc. (NasdaqGS:KNTE).

Kinnate Biopharma Inc. (NasdaqGS:KNTE) completed the acquisition of acquired the remaining stake in Kinnjiu Biopharma Limited on February 17, 2023.